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ABSTRACT
Objectives Hospital death is comparatively 
common in people with haematological 
cancers, but little is known about patient 
preferences. This study investigated actual and 
preferred place of death, concurrence between 
these and characteristics of preferred place 
discussions.
Methods Set within a population- based 
haematological malignancy patient cohort, 
adults (≥18 years) diagnosed 2004–2012 who 
died 2011–2012 were included (n=963). Data 
were obtained via routine linkages (date, 
place and cause of death) and abstraction of 
hospital records (diagnosis, demographics, 
preferred place discussions). Logistic regression 
investigated associations between patient and 
clinical factors and place of death, and factors 
associated with the likelihood of having a 
preferred place discussion.
Results Of 892 patients (92.6%) alive 2 weeks 
after diagnosis, 58.0% subsequently died in 
hospital (home, 20.0%; care home, 11.9%; 
hospice, 10.2%). A preferred place discussion 
was documented for 453 patients (50.8%). 
Discussions were more likely in women 
(p=0.003), those referred to specialist palliative 
care (p<0.001), and where cause of death was 
haematological cancer (p<0.001); and less likely 
in those living in deprived areas (p=0.005). 
Patients with a discussion were signiicantly 
(p<0.05) less likely to die in hospital. Last 
recorded preferences were: home (40.6%), 
hospice (18.1%), hospital (17.7%) and care 
home (14.1%); two- thirds died in their inal 
preferred place. Multiple discussions occurred 
for 58.3% of the 453, with preferences varying 
by proximity to death and participants in the 
discussion.
Conclusion Challenges remain in ensuring that 
patients are supported to have meaningful end- 
of- life discussions, with healthcare services that 
are able to respond to changing decisions over 
time.
IntROduCtIOn
Arising in blood and lymph forming 
tissues, haematological malignancies 
(leukaemias, lymphomas and myelomas) 
are collectively the fourth most common 
cancer among men (after prostate, lung 
and bowel) and women (after breast, lung 
and bowel) in the UK and other economi-
cally developed countries.1 2 With diverse 
treatments and outcomes, WHO currently 
recognises more than 100 disease subtypes, 
some of which are potentially curable 
but many more that are not.3 Chronic 
myeloproliferative neoplasms (MPN), for 
example, are considered incurable but 
symptoms can be treated and the disease 
normally progresses slowly over time. In 
contrast, acute myeloid leukaemia (AML) 
is aggressive and, although potentially 
curable for some with intensive chemo-
therapy, it is often rapidly fatal.
Evidence indicates that the end- of- life 
pathways of patients with haematological 
malignancies differ from those of people 
with other cancers. They are, for example, 
comparatively less likely to receive 
specialist palliative care (SPC); tend to 
have fewer, and shorter, hospice stays; are 
more likely to die in hospital; and are more 
likely to receive aggressive care in their 
final days.47 Importantly, these factors are 
often considered indicators of suboptimal 
end- of- life care.8 There has been increasing 
research interest in the care pathways 
and needs of this patient group in recent 
years,9 with closer integration between 
haematology and palliative care services 
recommended by the UK Department of 
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Health.10 The American Society for Clinical Oncology 
has also published guidelines recognising that palliative 
care services should be integrated into routine healthcare 
for patients with advanced cancer, though no specific 
recommendation was made regarding haematology.9
Dying in a preferred place is generally considered a 
quality marker for good end- of- life care,11 with pref-
erence for home death predominating.12 However, 
current evidence suggests that many patients with 
haematological malignancies do not die in their 
preferred place.13 The present study investigates this 
issue within the UKs population- based Haematolog-
ical Malignancy Research Network (HMRN: www. 
hmrn. org), which was specifically established to 
provide information about such subjects.14 The aim 
of the study is threefold: (1) investigate the patient 
and clinical characteristics associated with actual and 
preferred place of death in patients with haemato-
logical malignancies, (2) determine the concurrence 
between actual and preferred place of death and (3) 
characterise discussions in secondary care about pref-
erences including the decisions made, the people 
involved and changes over time.
MethOds
study setting
HMRN was established in 2004, has a catchment of 
around 4 million people and operates under a legal 
basis that permits data collection from medical records 
in 14 hospitals that deliver care in the area, without 
explicit patient consent. All haematological cancer 
diagnoses are made and coded by specialist haemato-
pathologists in the Haematological Malignancy Diag-
nostic Service (HMDS: www. hmds. info), using current 
classification systems.3 Further details of HMRNs 
population, structure, ethical approvals, data collec-
tion methods and linkages are reported elsewhere.14 
Briefly, demographic and clinical data are extracted 
from the hospital records of all patients, and supple-
mented via routine linkage to national data sources, 
including the Medical Research Information Service 
(MRIS), for information on deaths.
Population
)RU WKH SUHVHQW VWXG\ DOO DGXOWV  \HDUV LQ WKH
HMRN cohort who were newly diagnosed with a 
haematological malignancy between 1 September 
2004 (when HMRN began) and 2012, and who died 
between 1 September 2011 and 31 August 2012 (to 
match the most recent death notifications from MRIS 
at the time of data collection) were eligible for inclu-
sion (n=1041). Seventy- eight (7.5%) patients whose 
medical records could not be traced by their treating 
hospital were excluded, many of whom died outside 
the study area (n=29, 37.2%).
study variables
Study variables were selected based on previous litera-
ture and insight from clinical members of the steering 
committee. Routinely collected diagnostic and demo-
graphic data (diagnosis, date of diagnosis, age at diag-
nosis and death, gender and socioeconomic status) 
were extracted from HMDS and medical records. 
An area- based measure of the income domain of the 
Index of Multiple Deprivation was used as the marker 
of socioeconomic status and was categorised into three 
distinct groups (1=most affluent; 3=least affluent).15 
MRIS provided date, place and cause of death; and 
International Classification of Diseases, 10th Revision 
codes C91C96 and D46D48 indicate death due to 
haematological malignancy.16 Time from diagnosis to 
death was calculated using the difference between the 
date of diagnosis and date of death (06 months; 6+ 
months).
Additional data regarding hospital- based outpatient 
or inpatient discussions about preferred place of death 
were collected from the hospital records of eligible 
patients who survived over 14 days after diagnosis. 
Data were collected by trained study nurses using an 
extraction form containing the variables of interest, 
with instructions for completion defined in a detailed 
protocol. The form and protocol were written by 
the lead investigator (DAH), piloted by the nurses, 
amended during working group meetings and finalised 
by the steering committee. The nurses routinely exam-
ined each section of the medical records, including 
all handwritten notes, typed letters and any other 
material that might have contained information about 
advance planning discussions. Forms were checked for 
quality and consistency at study meetings and during 
data inputting.
Preferred place of death was grouped into five cate-
gories: home, hospital, care home, hospice or 
unknown; the latter including discussions that did 
not result in a decision. Discussions were categorised 
as involving the patient (alone or with relatives) or 
involving relatives only. The number of discussions 
recorded per patient was counted and categorised 
as one or more than one. Where multiple discus-
sions were found, the last recorded discussion before 
death was used in the analysis. For example, concur-
rence between actual and preferred place of death 
was achieved if the patient died in their last recorded 
preferred place. Information about hospital- based SPC 
referrals and social circumstances (living alone or not) 
were also abstracted.
statistical analyses
Logistic regression was used to calculate ORs and 
95% CIs for associations between patient and clinical 
factors and (1) place of death (hospital, home, care 
home, hospice), and (2) the likelihood of a discus-
sion about preferred place of death. Adjustment for 
age and gender did not alter the results and therefore 
unadjusted values are reported throughout. Missing 
data were not imputed; pairwise deletion was used in 
Protected by copyright.
 o
n
 M
ay 12, 2020 at The Librarian J B M
orrell Library.
http://spcare.bmj.com/
BM
J Support Palliat Care: first published as 10.1136/bmjspcare-2019-002097 on 11 May 2020. Downloaded from 
3Sheridan R, et al. BMJ Supportive & Palliative Care 2020;0:1–10. doi:10.1136/bmjspcare-2019-002097
Original research
analyses where appropriate. All analyses were carried 
out using Stata V.15.1.17
Patient and public involvement
Patients were involved in all aspects of this work 
including: study design, the funding application, the 
steering group and dissemination activities.
Results
A total of 963 patients were included, with 23 haema-
tological malignancy subtypes. As expected, the most 
common were: diffuse large B- cell lymphoma (16.0%), 
myeloma (15.9%), AML (12.4%), myelodysplastic 
syndromes (11.3%), chronic lymphocytic leukaemia 
(9.4%) and MPN (8.1%).
The majority of patients were male (n=549, 57.0%) 
and the overall median age at diagnosis was 75.8 years 
(IQR 66.482.9 days; table 1). Patients with MPNs 
tended to be older at diagnosis and death. Median 
survival ranged from 3 months (AML) to 39 months 
(MPN).
Haematological malignancy was considered the 
underlying cause of death in 68% of patients (table 1); 
the other main causes being ischaemic heart diseases 
(n=45, 4.7%) and chronic lower respiratory diseases 
(n=33, 3.4%). Approximately one- third (35.8%) of 
patients were referred to hospital- based SPC services, 
with a median time from diagnosis to SPC referral of 
13.5 months (IQR 2.838.9). Patients with AML had 
the shortest interval (2.8 months, IQR 1.110.1) and 
those with MPN the longest (55 months, IQR 20.2
69.4). Seventy- one patients (7.3%) died within 14 
days of diagnosis and were removed from subsequent 
analyses, as hospital death was considered likely to be 
unavoidable in this group.
Place of death
Varying with patient and clinical characteristics, the 
most common place of death was hospital (n=517, 
58%), followed by home (n=178, 20%), care home 
(n=106, 11.9%) and hospice (n=91, 10.2%). Table 2 
presents the demographic and clinical characteristics 
of patients distributed by actual place of death.
A number of factors were significantly associated 
with place of death (table 3). As expected, compared 
with those dying in hospital, people dying in a care 
home were more likely to be older (OR 11.42, 95% CI 
5.21 to 25.10) and female (OR 2.46, 95% CI 1.60 to 
3.77). In common with patients dying at home, they 
were also more likely to have an MPN, the most indo-
lent of included diagnoses and typically managed in 
the home setting; the corresponding ORs were 2.16 
(95% CI 1.04 to 4.49) and 2.30 (95% CI 1.13 to 4.69) 
for care home and home, respectively. As expected, 
patients who died closer to diagnosis were less likely 
to die at home (OR 0.65, 95% CI 0.43 to 0.99) or in 
a hospice (OR 0.42, 95% CI 0.22 to 0.79); with those 
dying in a hospice being more likely to have lived alone 
(OR 1.70, 95% CI 1.07 to 2.69) and to have had an 
SPC referral (OR 5.85, 95% CI 3.54 to 9.66). Across 
all comparisons, patients who had a preferred place 
of death discussion recorded in their medical notes 
were more likely to die in a non- hospital setting (eg, 
hospital vs hospice: OR 5.24, 95% CI 3.07 to 8.94).
Preferred place of death discussions
Discussion(s) about preferred place of death were 
documented in the medical records of 50.8% of 
patients (table 4). Patients who had a preferred place 
discussion were more likely to be female (OR 1.51, 
95% CI 1.15 to 1.97, p=0.003), while patients living 
in the most deprived areas were less likely to have 
had a discussion (OR vs least deprived 0.69, 95% CI 
0.50 to 0.96, p=0.005). A smaller proportion of these 
patients died of their haematological malignancy 
(most deprived, 63.9%; least deprived, 71.3%) or 
had evidence of SPC referral (most deprived, 27.3%; 
least deprived, 44.8%). Notably, both of these factors 
were significantly associated with increased likelihood 
of having a preferred place discussion (haematolog-
ical cause of death: OR 2.52, 95% CI 1.89 to 3.37, 
p<0.001; SPC referral: OR 8.93, 95% CI 6.40 to 
12.46, p<0.001). Age at death, time between diag-
nosis and death, and the patients social circumstances 
had no significant impact on whether a discussion was 
recorded.
The most common last recorded preference was for 
home death (n=184, 40.6%), followed by hospice 
(n=82, 18.1%), hospital (n=80, 17.7%) and care home 
(n=64, 14.1%). Not including those with an unknown 
preference, 271 (66.1%) patients died in their final 
preferred place (table 5). Almost all those with hospital 
listed as the preferred place died in hospital (n=77, 
96.3%) while roughly half wanting to be at home died 
at home (n=95, 51.6%). When patients did not die in 
their preferred place, or had an unknown preference, 
the most common place of death was hospital. The 
majority of last recorded discussions involved patients 
(n=323, 71.6%); this was most common when the 
preferred place was home (87%) and least common 
when the preferred place was hospital (48.1%). Prox-
imity to death was also important; when hospital was 
preferred, 85% of discussions were held within 7 days 
of death reducing to 50%, 35.9% and 25% if it was 
hospice, home or care home, respectively. Overall, 
median time from last discussion to death was 8 days 
(IQR 329).
Over half of those with a preferred place discus-
sion (n=264, 58.3%) had more than one discussion 
(range 17), with variation seen by last recorded pref-
erence (hospice, 70.7%; hospital, 70.0%; unknown, 
60.5%; care home, 50.0%; home, 50.0%). While 
118 (44.7%) stated the same preference at their first 
and last recorded discussion, 146 (55.3%) changed 
(table 5). For patients whose last recorded preference 
was hospital, 14.3% had the same initial preference. 
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Table 1 Demographic and clinical characteristics distributed by diagnosis (n=963)
All patients
DLBCL*
n=154 (16.0%)
Myeloma
n=153 (15.9%)
AML†
n=119 (12.4%)
MDS‡
n=109 (11.3%)
CLL§
n=91 (9.4%)
MPN¶
n=78 (8.1%)
Other
n=259 (26.9%)
Gender
Male (%) 549 (57.0) 78 (50.6) 87 (56.9) 66 (55.5) 74 (67.9) 55 (60.4) 39 (50.0) 150 (57.9)
Age (years, median IQR)††
At diagnosis 75.8 (66.4–82.9) 75.0 (64.5–81.5) 72.1 (63.6–80.4) 76.3 (66.2–83.4) 76.1 (68.3–82.2) 76.1 (69.8–84.2) 80.7 (74.8–87.2) 75.9 (66.3–83.4)
At death 77.9 (68.6–85.0) 75.9 (66.3–83.2) 74.6 (66.8–83.3) 77.5 (67.6–83.9) 77.9 (72.2–83.2) 79.5 (73.2–85.9) 83.8 (77.9–89.9) 78.1 (69.3–85.2)
IMD** category (%)
Most afluent 1 360 (37.4) 59 (38.3) 63 (41.2) 45 (37.8) 44 (40.4) 30 (33.3) 27 (34.6) 92 (35.5)
  2 319 (33.2) 50 (32.5) 50 (32.7) 39 (32.8) 26 (23.9) 30 (33.3) 31 (39.7) 93 (35.9)
Most deprived 3 283 (29.4) 45 (29.2) 40 (26.1) 35 (29.4) 39 (35.8) 30 (33.3) 20 (25.6) 74 (28.6)
Time from diagnosis to death (%)
0–6 months 282 (29.3) 77 (50.0) 40 (26.1) 72 (60.5) 14 (12.8) 14 (15.4) 6 (7.7) 59 (22.8)
6+ months 681 (70.7) 77 (50.0) 113 (73.9) 47 (39.5) 95 (87.2) 77 (84.6) 72 (92.3) 200 (77.2)
Median (IQR) 17.1 (4.4–42.8) 6.2 (1.1–25.8) 25.6 (5.6–42.9) 3.1 (0.9–14.4) 20.4 (8.7–35.4) 36.7 (10.7–52.7) 39.8 (21.3–55.4) 18.0 (7.3–45.4)
Underlying cause of death‡‡
Haematological malignancy (%) 655 (68.0) 117 (76.0) 118 (77.1) 107 (89.9) 73 (67.0) 42 (46.2) 21 (26.9) 177 (68.3)
Hospital- based SPC referral (n=892)§§
Yes (%) 319 (35.8) 50 (38.8) 61 (42.1) 54 (53.5) 29 (27.1) 29 (32.6) 11 (14.1) 85 (35.0)
*Diffuse large B- cell lymphoma.
†Acute myeloid leukaemia.
‡Myelodysplastic syndromes.
§Chronic lymphocytic leukaemia.
¶Myeloproliferative neoplasms.
**Index of Multiple Deprivation (income domain): one patient with missing data.
††IQR.
‡‡Derived from death certiicate data, Medical Research Information Service.
§§Specialist palliative care: 71 patients with no data collection due to death within 14 days.
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Table 2 Demographic and clinical characteristics distributed by actual place of death (n=892)
All deaths
Actual place of death
Hospital n = 
517 (58.0%)
Home n = 178 
(20.0%)
Care home n = 106 
(11.9%)
Hospice n = 91 
(10.2%)
Gender
Male (%) 520 (58.3) 319 (61.7) 108 (60.7) 42 (39.6) 51 (56.0)
Age at death (years, %)
≤74 363 (40.7) 231 (44.7) 80 (44.9) 7 (6.6) 45 (49.5)
75+ 529 (59.3) 286 (55.3) 98 (55.1) 99 (93.4) 46 (50.5)
IMD category* (%)
Most afluent 1 328 (36.8) 196 (38.0) 63 (35.4) 35 (33.0) 34 (37.4)
2 303 (34.0) 165 (32.0) 64 (36.0) 44 (41.5) 30 (33.0)
Most deprived 3 260 (29.2) 155 (30.0) 51 (28.7) 27 (25.5) 27 (29.7)
First diagnosis (%)
DLBCL† 129 (14.5) 71 (13.7) 23 (12.9) 22 (20.8) 13 (14.3)
Myeloma 145 (16.3) 90 (17.4) 35 (19.7) 11 (10.4) 9 (9.9)
AML‡ 101 (11.3) 61 (11.8) 22 (12.4) 7 (6.6) 11 (12.1)
MDS§ 107 (12.0) 69 (13.3) 22 (12.4) 6 (5.7) 10 (11.0)
CLL¶ 89 (10.0) 49 (9.5) 18 (10.1) 12 (11.3) 10 (11.0)
MPN** 79 (8.7) 34 (6.6) 20 (11.2) 18 (17.0) 6 (6.6)
Other 243 (27.2) 143 (27.7) 38 (21.3) 30 (28.3) 32 (35.2)
Time from diagnosis to death (%)
0–6 months 211 (23.7) 138 (26.7) 34 (19.1) 27 (25.5) 12 (13.2)
6+ months 681 (76.3) 379 (73.3) 144 (80.9) 79 (74.5) 79 (86.8)
Underlying cause of death††
Haematological malignancy (%) 602 (67.5) 353 (68.3) 117 (65.7) 64 (60.4) 68 (74.7)
Patient lived alone
Yes (%) 247 (27.7) 144 (27.9) 45 (25.3) 22 (20.8) 36 (39.6)
Hospital- based SPC‡‡ referral
Yes (%) 319 (35.8) 167 (32.3) 66 (37.1) 19 (17.9) 67 (73.6)
Preferred place of death discussion recorded
Yes (%) 453 (50.8) 217 (42.0) 103 (57.9) 61 (57.5) 72 (79.1)
*Index of Multiple Deprivation (income domain): one patient with missing data.
†Diffuse large B- cell lymphoma.
‡Acute myeloid leukaemia.
§Myelodysplastic syndromes.
¶Chronic lymphocytic leukaemia.
**Myeloproliferative neoplasms.
††Derived from death certiicate data, Medical Research Information Service.
‡‡Specialist palliative care.
When home was the last choice, 80.4% also chose 
home at first discussion.
dIsCussIOn
Principal indings
The most common place of death was hospital, with 
the lowest frequency seen in those with more indolent 
disease subtypes. Half of all patients in the study had 
a recorded preferred place of death discussion. This 
was significantly more likely for women, people with 
SPC referrals and those dying from their haematolog-
ical cancer, and less likely in patients living in deprived 
areas. As expected, the most common preference was 
for home death, especially at first discussion; although 
one in five final discussions resulted in preference 
for hospital death. Two- thirds died in their preferred 
place including most of those preferring hospital and 
around half wanting to die at home. Having a discus-
sion significantly increased the likelihood of non- 
hospital death. Most patients had multiple discussions, 
clearly demonstrating an ongoing, dynamic process, 
with decisions determined by who was involved in the 
conversation (patients and/or relatives) and proximity 
to death.
strengths and limitations
This is the largest study we are aware of to examine 
preferred and actual place of death, and the charac-
teristics of associated discussions in patients with 
haematological malignancies. It is also the only work 
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Table 3 OR and 95% CI of patient demographic and clinical characteristics associated with actual place of death*
Home Care home Hospice
OR (95% CI) P value OR (95% CI) P value OR (95% CI)
P 
value
Gender
Male 1.00 – 1.00 – 1.00 –
Female 1.04 (0.74 to 1.48) 0.808 2.46 (1.60 to 3.77) <0.001 1.26 (0.81 to 1.98) 0.309
Age at death (years)
≤74 1.00 – 1.00 – 1.00 –
75+ 0.99 (0.70 to 1.39) 0.951 11.42 (5.21 to 25.10) <0.001 0.83 (0.53 to 1.29) 0.400
IMD category*
Most afluent 1 1.00 – 1.00 – 1.00 –
2 1.21 (0.81 to 1.81) 0.363 1.49 (0.92 to 2.44) 0.109 1.05 (0.62 to 1.79) 0.863
Most deprived 3 1.02 (0.67 to 1.57) 0.914 0.98 (0.57 to 1.68) 0.929 1.00 (0.58 to 1.74) 0.988
First diagnosis
DLBCL† 1.00 – 1.00 – 1.00 –
Myeloma‡ 1.52 (0.85 to 2.75) 0.159 0.47 (0.22 to 1.03) 0.058 0.76 (0.32 to 1.82) 0.540
AML§ 1.10 (0.57 to 2.09) 0.794 0.36 (0.15 to 0.89) 0.027 1.01 (0.43 to 2.37) 0.988
MDS¶ 1.23 (0.64 to 2.37) 0.535 0.41 (0.17 to 1.01) 0.052 1.03 (0.43 to 2.49) 0.942
CLL** 1.38 (0.69 to 2.78) 0.364 0.96 (0.44 to 2.09) 0.921 1.42 (0.58 to 3.46) 0.443
MPN†† 2.30 (1.13 to 4.69) 0.021 2.16 (1.04 to 4.49) 0.038 1.28 (0.45 to 3.62) 0.647
Other 0.97 (0.55 to 1.72) 0.925 0.81 (0.44 to 1.47) 0.481 1.47 (0.74 to 2.95) 0.273
Time from diagnosis to death (months)
0–6 months 0.65 (0.43 to 0.99) 0.044 0.94 (0.58 to 1.51) 0.795 0.42 (0.22 to 0.79) 0.007
6+ months 1.00 – 1.00 – 1.00 –
Underlying cause of death‡‡
Haematological malignancy 0.89 (0.62 to 1.28) 0.531 0.71 (0.46 to 1.09) 0.116 1.37 (0.83 to 2.28) 0.220
Other 1.00 – 1.00 – 1.00 –
Patient lived alone§§
Yes 0.88 (0.59 to 1.29) 0.506 0.68 (0.41 to 1.13) 0.134 1.70 (1.07 to 2.69) 0.025
No/unknown 1.00 – 1.00 – 1.00 –
Hospital- based SPC¶¶ referral
Yes 1.24 (0.87 to 1.72) 0.245 0.46 (0.27 to 0.78) 0.004 5.85 (3.54 to 9.66) <0.001
No 1.00 – 1.00 – 1.00 –
Preferred place of death discussion recorded
Yes 1.90 (1.34 to 2.68) <0.001 1.87 (1.34 to 2.68) 0.005 5.24 (3.07 to 8.94) <0.001
No 1.00 – 1.00 – 1.00 –
Bold font indicates statistical signiicance.
*Reference category is hospital death.
†Index of Multiple Deprivation (income domain): one patient with missing data.
‡Diffuse large B- cell lymphoma.
§Acute myeloid leukaemia.
¶Myelodysplastic syndromes.
**Chronic lymphocytic leukaemia.
††Myeloproliferative neoplasms.
‡‡Derived from death certiicate data, Medical Research Information Service.
§§Patient lived alone: ‘No’ includes 24 patients where it was ‘unknown’.
¶¶Specialist palliative care: ‘No’ includes 25 patients where SPC is ‘Unknown’.
examining decisions made in this context by relatives 
alone. Setting the study within a well- established 
population- based cohort and hand searching secondary 
care records (electronic and paper) for information 
ensured data collection was thorough and all relevant 
discussions and decisions were identified. We inten-
tionally included all patients newly diagnosed with 
haematological malignancies between 2004 and 2012, 
who died during a 1- year period. This ensured vari-
able follow- up time (maximum 7 years; minimum of 
2 weeks) and inclusion of patients with differing expe-
riences/survival outcomes, thereby facilitating exam-
ination of issues such as how place of death is impacted 
by survival duration, and time from SPC referral to 
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Table 4 Likelihood of patients having a preferred place of 
death discussion by demographic and clinical characteristics
Factors
Preferred place 
discussion recorded
OR (95% CI)
Yes
n=453 
(50.8%)
No
n=439 
(49.2%)
Gender
Male 242 (46.5) 278 (53.5) 1.00
Female 211 (56.7) 161 (43.3) 1.51 (1.15 to 1.97)
Age at death (years)
≤74 192 (52.9) 171 (47.1) 1.15 (0.88 to 1.51)
75+ 261 (49.3) 268 (50.7) 1.00
IMD category*
Most afluent 1 189 (57.6) 139 (42.4) 1.00
  2 137 (45.2) 166 (54.8) 0.61 (0.44 to 0.83)
Most deprived 3 126 (48.5) 134 (51.5) 0.69 (0.50 to 0.96)
Time from diagnosis to death (months)
0–6 months 113 (53.6) 98 (46.4) 1.16 (0.85 to 1.58)
6+months 340 (49.9) 341 (50.1) 1.00
Underlying cause of death†
Haematological 
malignancy
350 (58.1) 252 (41.9) 2.52 (1.89 to 3.37)
Other 103 (35.5) 187 (64.5) 1.00
Patient lived alone‡
Yes 138 (55.9) 109 (44.1) 1.33 (0.99 to 1.78)
No 315 (48.8) 330 (51.2) 1.00
Hospital- based SPC referral§
Yes 261 (81.8) 58 (18.2) 8.93 (6.40 to 12.46)
No 192 (33.5) 381 (66.5) 1.00
Bold font indicates statistical signiicance.
*Index of Multiple Deprivation (income domain): one patient with 
missing data.
†Derived from death certiicate data, Medical Research Information 
Service.
‡No includes 24 where patient living circumstances were ‘unknown’.
§Specialist palliative care: ‘No’ includes 25 patients where SPC is 
‘Unknown’.
death. Including all 20112012 deaths ensured find-
ings reflected contemporary end- of- life clinical prac-
WLFH $V DOO DGXOW GHDWKV  \HDUV UHJDUGOHVV RI
gender, deprivation and diagnosis) were included, our 
study is likely to be generalisable to other locations 
with similar healthcare systems and settings.
Data collection relied on information written in 
medical records by clinical staff, which did not always 
specify the exact purpose of discussions. Unclear 
documentation was examined during study meetings 
and included if it was agreed that the excerpt related 
to place of care or place of death. These are clearly 
different issues,18 however, and improvements in the 
documentation of advance care planning may mean it 
is possible to distinguish between these issues in the 
future. Due to difficulties accessing data from multiple 
settings, we focused on hospital activities. Conse-
quently, data regarding discussions and SPC referrals 
in primary and community care are not included. 
While data collection took place several years ago, 
our findings are consistent with more recent data,19 
and preferred and actual place of death remains an 
important issue in both research and practice, along-
side advance planning more generally (eg, http:// 
respectprocess. org. uk).
Comparison with existing literature
Two previous studies involving patients with haema-
tological malignancies have observed higher propor-
tions of preferred place discussions than the current 
study,11 20 possibly due to these projects including 
only patients known to SPC servicesthe associa-
tion between SPC referral and likelihood of a discus-
sion being clearly highlighted in the current study, 
and other work.13 Studies examining likelihood of a 
discussion by gender also found women more likely to 
have discussed preferences,13 with men said to be more 
reluctant to discuss their impending death, even after 
interventions to redress this imbalance.21
Although we could not find evidence to corroborate 
the relationship between increasing deprivation and 
decreased preference discussions in the haematology 
context, studies examining related issues provide 
compelling evidence of other disadvantages, including 
fewer SPC referrals, more hospital deaths (though 
not statistically significant in the present study), and 
indeed, poorer quality care.19 22 Across all included 
patients in our study, we found those living in increas-
ingly deprived areas were comparatively more likely 
to die from comorbidities rather than their haemato-
logical malignancy. The existence of such comorbid-
ities may lead to patients being managed by multiple 
specialities,13 thus possibly obscuring responsibility for 
instigating end- of- life conversations and resulting in 
missed opportunities.
The characteristics we noted about discussions 
(recurrent conversations, changing preferences and 
disparity between patient and relatives views) have 
been reported in other studies.13 18 23 24 As expected, 
preferences generally shifted from death at home 
towards hospital death.13 19 A comprehensive system-
atic review reported that 20% of patients changed 
their preferences (range 2%80%).25 In our study 
population, we observed a higher proportion of 
change (55.3%), which may be due to circumstance as 
much as choice. For example, uncertain disease trajec-
tories and prognoses are common in haematological 
malignancies and may cause sudden deterioration and 
death, leaving little time to organise transfer home, or 
to a hospice, to die.24 2628 Alternatively, the inability 
of patients or family/carers to cope at home may mean 
hospital becomes the preferred, or de facto, place of 
death, even when home was preferred and planned.24 29 
This may also explain some of the observed discrepan-
cies between patient and family members preferences.
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Table 5 Actual place of death, patient involvement and number of discussions by the last recorded preferred place, n=453 with 
discussion recorded
All deaths
Preferred place at discussion closest to death (%)
Hospital
n=80 (17.7%)
Home
n=184 (40.6%)
Care home
n=64 (14.1%)
Hospice
n=82 (18.1%)
Unknown
n=43 (9.5%)
Actual place of death
Hospital 217 (47.9) 77 (96.3) 66 (35.9) 15 (23.4) 28 (34.1) 31 (72.1)
Home 103 (22.7) 2 (2.5) 95 (51.6) – 1 (1.2) 5 (11.6)
Care home 61 (13.5) 1 (1.3) 6 (3.3) 48 (75.0) 2 (2.4) 4 (9.3)
Hospice 72 (15.9) – 17 (9.2) 1 (1.6) 51 (62.2) 3 (7.0)
Involved in discussion (n=451)*
Patient (alone/with relative) 323 (71.6) 38 (48.1) 160 (87.0) 32 (50.0) 65 (80.2) 28 (65.1)
Relative(s) only 122 (28.4) 41 (51.9) 24 (13.0) 32 (50.0) 16 (19.8) 15 (34.9)
Number of discussions
One 189 (41.7) 24 (30.0) 92 (50.0) 32 (50.0) 24 (29.3) 17 (39.5)
More than one 264 (58.3) 56 (70.0) 92 (50.0) 32 (50.0) 58 (70.7) 26 (60.5)
  No change in preference 118 (44.7) 8 (14.3) 74 (80.4) 13 (40.6) 13 (22.4) 10 (38.5)
*Not including those whose involvement was ‘Unknown’ (n=2).
Our observed concurrence between preferred and 
actual place of death (66.1%) is similar to earlier 
research in the same area (63.4%),13 and well within 
the range of studies included in a systematic review 
(30%89%),30 although the latter incorporated both 
cancer and non- cancer studies and noted difficulties 
comparing work due to varied settings, populations 
and methods. Others have also reported large numbers 
of hospital deaths among patients with haematological 
malignancies,6 and described indecision and unknown 
preferences, either because patients had not been 
asked, were unwilling to have a discussion, or had 
no preference.23 26 Research described those without 
a discussion dying in hospital more often,11 13 20 with 
those surviving longer being more likely to die at home 
or in hospice,31 probably because there was more time 
to arrange this.27
Implications for practice and future research
Having a preferred place of death discussion, and the 
decision documented, is important if patient pref-
erences at the end- of- life are to be achieved.11 13 20 
Ensuring all patients have the opportunity to discuss 
this in a supportive, pragmatic and compassionate 
way is therefore paramount. This could be facilitated 
by strengthened training for medical professionals to 
improve their ability and confidence in end- of- life 
discussions.32 The increased likelihood of preference 
discussions, and of death in hospice in those with SPC 
input suggests further haematology/SPC integration 
can also be beneficial. Greater support may also be 
required for haematology staff providing end- of- life 
care and advance planning; while some consider this a 
necessary skill and a rewarding experience,27 28 33 issues 
are reported with providing adequate emotional and 
psychological support for patients and families on busy 
acute wards.28 Regarding documentation of discussions 
and decisions, the introduction of the Electronic Palli-
ative Care Coordinating Systems (EPaCCS) in England 
may facilitate recording between care settings, though 
challenges implementing EPaCCS remain.34
Despite some changes in place of death over time, 
hospital death will likely predominate into the future.35 
It is therefore vital that measures are put in place in 
this setting to improve the experiences of patients 
and their families at this time.36 While choice in dying 
remains important, home death is increasingly consid-
ered to have become a quality marker in itself , rather 
than a true, adequately resourced choice that can 
meet changing needs.37 Indeed, some consider end- of- 
life hospitalisation to be unavoidable and justified38; 
with the delivery of 24 hours quality care by experts, 
being pain/symptom free, having family present 
and not being a burden said to have greater signifi-
cance.36 39 Importantly, where preferences are not met 
and hospital- death occurs, bereaved relatives often 
later describe hospital as the right place.19 24 Find-
ings such as these bring into question the suitability 
of concurrence between preferred and actual place of 
death as an indicator of quality36 40 Further research 
is required into the impact of deprivation and other 
socioeconomic factors on preferences, reasons for not 
discussing place of death, not stating a preference or 
changing preference. More also needs to be known 
about the role of haematologists and specialist nurses 
in discussing end- of- life preferences, to understand if 
and how gaps in advance planning could be addressed.
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